Riskpilot← Back to searchSign inGet full accessGYNHARSTAD AS
ASActiveOrg 913707079Spesialistklinikken Håkons Gate 4, 9405 HarstadMedical specialists activities · NACE 8622Est. 20141 employees
Revenue 2024
NOK 3,8M
+1% vs 2023
EBITDA margin
39.0%
-8% vs 2023
Equity ratio
61.7%
Financial strength
Net profit 2024
NOK 1,2M
-5% vs 2023
| Revenue | NOK 3,8M | +1% |
| EBITDA | NOK 1,5M | -8% |
| Net profit | NOK 1,2M | -5% |
| Total assets | NOK 2,8M | -9% |
| Equity | NOK 1,7M | -32% |
| Employees | 1 | — |
Legal name
GYNHARSTAD AS
Org number
913707079
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
2. juni 2014
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utøvelse av spesialistlege- og andre helsetjenester, omsetning av medisinsk utstyr samt annen virksomhet som naturlig faller sammen med dette, herunder investering i andre foretak.
Address
Spesialistklinikken Håkons Gate 4, 9405 Harstad
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 563 | 3 679 | 3 329 | 3 808 | 3 829 |
| Staff expenses | −1 199 | −1 186 | −1 191 | −836 | −1 028 |
| EBITDA | 1 018 | 1 012 | 697 | 1 628 | 1 493 |
| Depreciation & amort. | −26 | −65 | −66 | −7 | −2 |
| EBIT | 991 | 947 | 632 | 1 620 | 1 490 |
| Net financials | 2 | 0 | 1 | 6 | 49 |
| Profit before tax | 993 | 947 | 632 | 1 627 | 1 540 |
| Tax | 219 | 209 | 139 | 358 | 340 |
| Net profit | 774 | 739 | 493 | 1 269 | 1 199 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 753 | 3 157 | 3 823 | 3 062 | 2 778 |
| Equity | 681 | 1 022 | 1 272 | 2 516 | 1 716 |
| Long-term debt | 20 | 20 | 16 | 16 | 16 |
| Short-term debt | 2 052 | 2 115 | 2 535 | 530 | 1 047 |
| Total debt | 2 072 | 2 135 | 2 551 | 546 | 1 063 |
EBITDA margin
39.0%
This company
15.8%
Market median
+147% vs market
20202024
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
20202024
Return on equity
69.9%
This company
18.4%
Market median
+280% vs market
20202024
Net profit margin
31.3%
This company
8.1%
Market median
+286% vs market
20202024
Asset turnover
1.38×
This company
1.12×
Market median
+23% vs market
20202024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2014 | |
| Board of Directors | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Morten Mangersnes As
GYNHARSTAD AS Board members of GYNHARSTAD AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Mangersnes | Chairman | 0 companies |
| Trine Ditløvsen | Board of Directors | 0 companies |